We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in our Lung Cancer. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Journal Scan / Research · September 26, 2022

First-in-Human Phase I Trial of TQ-B3139 in Patients With NSCLC With ALK and ROS1 Rearrangements

European Journal of Cancer


Additional Info

European Journal of Cancer
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements
Eur. J. Cancer 2022 Sep 01;173(xx)238-249, Y Ma, H Zhao, J Xue, L Liu, N Yang, Y Zhang, H Yang, S Hong, Y Xiong, Z Zhang, L Zeng, H Pan, C Zhou, Y Zhang, X Wang, X Han, X Wan, Y Shao, J Liu, Y Yang, Y Huang, Y Zhao, W Fang, S Li, L Zhang

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading